Insights on increasing the translational value of your preclinical development program.
May 12, 2026by MD Biosciences
The attrition rate for analgesic compounds remains stubbornly high. By some estimates, fewer than 2% of preclinical...
May 5, 2026by MD Biosciences
Species selection for GLP toxicology is one of those decisions that quietly shapes everything downstream. It influences...
Apr 28, 2026by MD Biosciences
The last five years have seen remarkable advances in in vitro and ex vivo pain research. Human DRG organoids,...
Apr 23, 2026by MD Biosciences
The gap between preclinical efficacy and clinical success in pain drug development is well-documented and widely...
Apr 21, 2026by MD Biosciences
Every preclinical pain program begins with a species decision, which shapes everything downstream, including endpoint...
.png?width=400&height=400&name=Untitled%20design%20(3).png)
